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Primary merosin (laminin α2 chain)-deficient congenital muscular dystrophy (CMD) is a uncommon and severe form 
of CMD, which is caused by the mutations in the laminin α2 chain gene. It is an autosomal recessively inherited form 
of muscular dystrophy that is associated with severe neonatal hypotonia, a high serum creatine kinase level, and abnormal 
brain imaging without intellectual dysfunction. We report a case of merosin-deficient CMD confirmed by the 
immunocytochemical analysis of the frozen muscle biopsy. This is the first case of merosin-deficient CMD in Korea. 
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증    례
Congenital muscular dystrophies (CMD) are a 
heterogeneous group of autosomal recessive neuro-
muscular disorders which is characterized by the early 
onset of muscle weakness starting at newborn or 
infant, high serum creatine kinase level, and dyst-
rophic pattern on the muscle biopsy.1,2 CMD is classi-
fied into several forms according to the clinical 
features and the primary gene defects.2 Among them, 
the primary deficiency of merosin is caused by the 
mutations in the laminin α2 (formerly named merosin) 
chain gene (LAMA2), which is located at chromosome 
6q2. Merosin-deficient CMD is the most common form 
of CMD in Europeans, while it is rare in Japan and 
has not reported in Korea.3 We report a case of 
merosin-deficient CMD with immunocytochemical an-
alysis of the cytoskeletal proteins. 
Case 
A 2-year-old girl presented with a neonatal deve-
lopmental delay. She was floppy at birth, and the 
motor milestones were delayed. She had difficulties in 
swallowing and walking, and was unable to control 
her head. A neurological examination showed ge-
neralized hypotonia with joint contractures in the 
knees and ankles, and proximal muscle weakness 
without muscle hypertrophy. There were no sensory 
abnormalities, and the deep tendon reflexes were 
preserved. There was no spasticity, Babinski signs, or 
ankle clonus. Her intellectual and speech development 
was normal. She had no history of neuromuscular 
diseases in her family. Serum creatine kinase level 
was moderately elevated to 914 IU/l (normal <200 
IU/l). The electrocardiogram showed sinus tachycardia 
Merosin Deficient Congenital Muscular Dystrophy: A Case with Immunocytochemical Analysis 
22권 6호 대한신경과학회지 681
Figure 1. Pathologic and immunocytochemical findings of pa-
tient (A, B, D) and normal control (C): There are dystrophic 
myopathic changes with degenerating and regenerating fibers, 
increased fiber size variations, perimysial fibrosis and fatty infi-
ltration (A: H&E, magnification ×100, B: trichrome gomori, 
magnification ×100). All muscle fibers stained positively to 
anti-merosin antibodies on the muscle surface membrane in the 
normal controls (C, magnification ×100).  In our patient, stai-
ning of the laminin α2 chain is negative (D, magnification ×
100).
(152 beat/min). The motor and sensory nerve con-
duction studies were normal. A needle electro-
myography (EMG) revealed a small and polyphasic 
motor unit action potentials in the left adductor longus 
and vastus medialis muscles. A muscle biopsy was 
performed in the left vastus lateralis muscle. There 
were dystrophic myopathic changes with degenerating 
and regenerating fibers, increased fiber size variations, 
perimysial fibrosis and fatty infiltration (Fig. 1-A). 
Gomori trichrome staining showed no ragged red 
fibers or nemaline bodies (Fig. 1-B). On ATPase 
staining, there was no fiber type grouping (figure not 
shown). Immunohistochemistry using antibodies against 
C-terminal of dystrophin (NCL-DYS2, Novocastra), 
N-terminal of dystrophin (NCL-DYS1, Novocastra), 
rod-domain of dystrophin (NCL-DYS3, Novocastra), 
laminin α2 (NCL-MEROSIN, Novocastra), and α- 
sarcoglycan (NCL-a-SARC, Novocastra), β-sarcoglycan 
(NCL-b-SARC, Novocastra), γ-sarcoglycan (NCL- 
g-SARC, Novocastra), δ-sarcoglycan (NCL-d-SARC, 
Novocastra), α-dystrophin (VIA4-1, Upstate), β- 
dystrophin (NCL-b-DG, Novocastra) and dysferin 
(NCL-Hamlet, Novocastra) was perform. The immuno-
reactivity against the laminin α2 chain was completely 
lost (Fig. 1-D) and α-dystroglycan was not expressed 
on some of the muscle membranes (Fig. 2). However, 
dystrophin, α-,β-,γ-,δ- sarcoglycan, dysferin and β- 
dystroglycan were normally expressed (Fig. 2). 
Discussion
Merosin (laminin-2 and -4), which contains the 
laminin α2 chains, is a major component of basal 
lamina (BL) of the skeletal muscle fiber. The BL 
surrounds each muscle fiber and is believed to have a 
critical role in maintaining the cytoarchitecture and 
homeostasis of the mature muscle fibers, along with 
the proper migration and proliferation of myogenic 
cells during myogenesis.4,5 Laminin α2 is expressed in 
numerous tissues including the skeletal muscle fibers, 
Schwann cells, the synaptic basal lamina of the 
peripheral nerves, the heart, trophoblast and skin. In 
skeletal muscle, the laminin (2 is located at the 
extracellular matrix and provides a link between the 
extracellular matrix and α-dystroglycan. Although 
laminin α2 deficiency is caused by merosin-deficient 
CMD, secondary reduction of laminin α2 had also been 
reported in other forms of CMD.6,7 In our case, the 
partial loss of α-dystroglycan is a secondary change 
caused by the selective loss of laminin (2, which is 
directly linked to α-dystroglycan.
The prevalence of CMD was estimated to be 
0.7/100000 in a sample from north-east Italy.8 While 
merosin deficient CMD accounts for approximately 
30% of the CMD cases in European countries, it 
occupies only 6% in Japan.3 Tome et al. first demon-
strated merosin deficient CMD in 13 out of 20 patients 
with non-Fukuyama CMD.1 
The human LAMA2 gene is located on 6q22-23. It 
spans over 260kb and consists of 64 exons.3 An 
analysis of the LAMA2 gene showed that nucleotide 
substitutions, small deletions, or insertions induce a 
complete merosin deficiency and a severe phenotype. 
Partial merosin deficient CMD is caused by a homo-
zygous missense mutation, a missense mutation 
associated with a nonsense mutation, in-frame dele-
tions in the LAMA2 gene, or nonsense mutations in 
the last exons of the G domain (exon58 to 64).9 
The clinical features have been described as severe 
neonatal hypotonia, joint contracture, inability to walk, 
highly elevated serum creatine kinase, alterations in 
the somatosensory and visual evoked potentials, and 
abnormalities in the brain images. Most patients have 
a normal intelligence. To date, treatment is not 
available but the conditions of life can be improved by 
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physiotherapy to reduce the contractures and arthro-
desis in order to limit deformation. 
We described a Korean patient with a merosin defi-
cient CMD, who showed typical clinical features. On 
immunocytochemistry, there was complete absence of 
laminin α2 with partial loss of α-dystroglycan. How-
ever, the other cytoskeletal proteins were present in 
the muscle membrane. This is the first case of Korean 
merosin-deficient CMD confirmed by immunocytoc-
hemical staining.
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Figure 2. Immunocytochemical staining of the C-terminal of dystrophin (Dys-C), 
N-terminal of dystrophin (Dys-N), rod-domain of dystrophin (Dys-R), dysferin (Dysf)
and the α-,β-,δ-,γ- sarcoglycans (Sar-α,Sar-β,Sar-δ,Sar-γ) and β-dystroglycan 
(β- DG). α-dystroglycan (α-DG) is partially expressed in the muscle membrane, 
however others show normally expressed (magnification ×100).
